How Stargardt Disease Causes Low Vision

Stargardt disease causes damage to the macula, the small central part of your retina that gives you detailed vision for reading, driving, and recognizing faces. Unlike age-related macular degeneration, which develops in older adults, Stargardt is passed down through families and usually begins in childhood or young adulthood. The condition belongs to a group of eye disorders known as inherited retinal dystrophies. ABCA4-related Stargardt is often referred to as STGD1.

We diagnose most cases in people between the ages of 6 and 20, though the condition can occasionally appear later in life. The disease affects approximately 1 in 8,000 to 10,000 people worldwide. Both males and females can develop Stargardt disease, and it occurs in all ethnic groups. Rare autosomal dominant Stargardt-like macular dystrophy is usually due to ELOVL4 (sometimes called STGD3).

Most cases of Stargardt result from mutations in a gene called ABCA4. This gene provides instructions for making a protein that helps remove waste products from light-sensing cells in your retina. When the ABCA4 gene does not work correctly, bisretinoid lipofuscin accumulates in the retinal pigment epithelium because ABCA4 in photoreceptors cannot efficiently clear vitamin A byproducts. Photoreceptor dysfunction occurs first, with subsequent RPE injury and then photoreceptor loss.

• The ABCA4 protein normally acts like a cleanup system in photoreceptor cells
• More than 1,000 different mutations in this gene have been identified
• The type of mutation can influence how severe your vision loss becomes
• Genetic testing can confirm which specific mutations you carry
• ABCA4 is expressed in rod and cone outer segments; RPE damage and photoreceptor loss are downstream effects

Stargardt follows an autosomal recessive pattern of inheritance in most cases. This means you must inherit one mutated copy of the ABCA4 gene from your mother and one from your father to develop the disease. Parents who carry only one mutated copy typically have normal vision themselves and may not know they are carriers.

If both parents are carriers, each of their children has a 25 percent chance of having Stargardt, a 50 percent chance of being a carrier, and a 25 percent chance of inheriting two normal gene copies. Rarely, Stargardt can follow a dominant pattern where inheriting just one mutated gene causes the disease, though these cases are much less common.

Vision loss from Stargardt most often starts during childhood or the teenage years. Many patients first notice problems when they struggle to read the board at school or find that words on a page look blurry. Some people do not experience noticeable symptoms until their 30s or 40s, especially if their genetic mutations cause a slower progression.

• The average age at diagnosis is between 10 and 20 years old
• Earlier onset often means faster progression of vision loss
• Some children may be diagnosed during routine school vision screenings

Diagnosis begins with a complete eye exam that includes dilation of your pupils with eye drops. Once your pupils are wide, we can use special lenses and bright lights to examine the back of your eye, including the retina and macula. In Stargardt disease, we often see characteristic yellow pisciform flecks around the posterior pole and areas of macular atrophy; the macula can take on a beaten bronze appearance when atrophic.

We also assess your visual acuity with various letter charts and may test how well you perceive contrast and colors. These baseline measurements help us track progression over time. The dilated exam allows us to evaluate the extent of macular damage and check for other retinal problems that might accompany or mimic Stargardt.

We use specialized cameras to take detailed color photographs of your retina. These images document the pattern and distribution of lipofuscin flecks, which have a distinctive yellowish appearance in Stargardt disease. Fundus photos provide a permanent record that we can compare during future visits to monitor whether flecks have increased or changed.

• Photos capture areas of atrophy where retinal cells have died
• Images help us explain findings to you and other members of your care team
• Serial photographs over months or years show the rate of disease progression
• The characteristic fleck pattern supports the diagnosis when combined with other tests

OCT is a painless scan that creates cross-sectional images of your retina, similar to an ultrasound but using light instead of sound waves. This technology lets us see the different layers of retinal tissue and measure their thickness. In Stargardt, we often find thinning of the outer retinal layers where photoreceptor cells have been lost.

OCT imaging reveals structural changes that may not be visible during a standard eye exam. We can identify early damage before you notice symptoms and track subtle changes over time. The detailed layer-by-layer view helps us assess disease severity and determine whether vision loss correlates with the amount of tissue damage.

FAF imaging detects the natural fluorescence of lipofuscin in your retina. Because lipofuscin glows when exposed to certain wavelengths of light, areas with heavy accumulation appear bright on FAF scans. This test is particularly useful for diagnosing and monitoring Stargardt, as the pattern of autofluorescence is often striking and characteristic.

• FAF shows lipofuscin buildup even before visible flecks appear on regular photos
• Dark areas on the scan indicate regions where photoreceptor cells have died
• The test is quick, non-invasive, and does not require any injections

Visual field testing maps your central and peripheral vision to detect areas of loss or reduced sensitivity. This helps us understand how much functional vision you retain in different parts of your visual field. The test involves looking at a screen and pressing a button when you see small lights appear.

Full-field electroretinography assesses how well your rod and cone cells respond to light. In advanced cases of Stargardt, ERG can detect generalized cone-rod involvement beyond the macula. Multifocal ERG provides more detailed information by mapping function across different macular regions, helping us localize areas of dysfunction.

Fluorescein angiography involves injecting a fluorescent dye into a vein and photographing how it flows through retinal blood vessels. Many patients with Stargardt show a classic dark choroid sign on this test, where the background layer under the retina appears darker than normal due to lipofuscin blocking fluorescence. Microperimetry can map retinal sensitivity directly over areas of scotomas. Dark adaptometry quantifies how long your eyes take to adjust to darkness, revealing delayed adaptation common in ABCA4 retinopathy.

We may recommend genetic testing to confirm the diagnosis and identify the specific mutations causing your Stargardt disease. A simple blood draw or saliva sample can be analyzed for changes in the ABCA4 gene and, less commonly, other genes linked to similar conditions. Genetic confirmation is especially helpful when clinical findings are unclear or when you want information about inheritance risks for family members.

Results can take several weeks and may provide details about which mutations you carry. Knowing your specific genetic profile may become important if targeted therapies are developed in the future. Genetic counseling can help you understand test results and what they mean for your children or siblings. Results may identify variants of uncertain significance, and not all disease-causing variants are detected; genetic counseling helps interpret findings for you and your family.